Raymond James Financial Inc. Buys Shares of 37,033 Biohaven Ltd. (NYSE:BHVN)

Raymond James Financial Inc. purchased a new position in shares of Biohaven Ltd. (NYSE:BHVN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 37,033 shares of the company’s stock, valued at approximately $1,384,000.

Other large investors have also made changes to their positions in the company. Barclays PLC boosted its holdings in shares of Biohaven by 87.6% in the 3rd quarter. Barclays PLC now owns 268,077 shares of the company’s stock valued at $13,396,000 after purchasing an additional 125,189 shares in the last quarter. Franklin Resources Inc. boosted its stake in Biohaven by 0.5% in the third quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock valued at $4,206,000 after buying an additional 412 shares in the last quarter. JPMorgan Chase & Co. grew its position in Biohaven by 85.4% in the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock valued at $40,448,000 after acquiring an additional 372,737 shares during the last quarter. Diversified Trust Co raised its stake in Biohaven by 16.6% during the fourth quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock worth $209,000 after acquiring an additional 795 shares in the last quarter. Finally, Weybosset Research & Management LLC lifted its holdings in shares of Biohaven by 23.9% in the fourth quarter. Weybosset Research & Management LLC now owns 13,645 shares of the company’s stock worth $510,000 after acquiring an additional 2,635 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BHVN shares. Robert W. Baird decreased their price target on shares of Biohaven from $60.00 to $57.00 and set an “outperform” rating on the stock in a report on Monday, April 28th. HC Wainwright reaffirmed a “buy” rating and set a $54.00 target price on shares of Biohaven in a research note on Tuesday, March 4th. William Blair upgraded Biohaven to a “strong-buy” rating in a research note on Thursday, April 24th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. dropped their target price on Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Fourteen equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Biohaven presently has a consensus rating of “Buy” and an average price target of $62.54.

Insider Activity

In other Biohaven news, Director John W. Childs purchased 32,700 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, with a total value of $996,369.00. Following the transaction, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 16.00% of the company’s stock.

Biohaven Trading Up 1.4 %

NYSE:BHVN opened at $22.76 on Friday. Biohaven Ltd. has a 12 month low of $15.79 and a 12 month high of $55.70. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of -2.43 and a beta of 1.18. The firm has a fifty day simple moving average of $24.91 and a two-hundred day simple moving average of $36.47.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Equities analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.